FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317548983> ?p ?o ?g. }

• W4317548983 endingPage "607" @default.
• W4317548983 startingPage "602" @default.
• W4317548983 abstract "OBJECTIVE To determine whether the benefits of dapagliflozin in patients with type 2 diabetes and chronic kidney disease (CKD) in the Dapagliflozin And Prevention of Adverse Outcomes in CKD trial (DAPA-CKD) varied by background glucose-lowering therapy (GLT). RESEARCH DESIGN AND METHODS We randomized 4,304 adults (including 2,906 with type 2 diabetes) with a baseline estimated glomerular filtration rate (eGFR) 25–75 mL/min/1.73 m2 and urinary albumin-to-creatinine ratio of 200–5,000 mg/g to dapagliflozin 10 mg or placebo once daily (NCT03036150). The primary end point was a composite of ≥50% eGFR decline, end-stage kidney disease, and kidney or cardiovascular cause of death. Secondary end points included a kidney composite end point (primary composite end point without cardiovascular death), a cardiovascular composite end point (hospitalized heart failure or cardiovascular death), and all-cause mortality. In this prespecified analysis, we investigated the effects of dapagliflozin on these and other outcomes according to baseline GLT class or number of GLTs. RESULTS The effects of dapagliflozin on the primary composite outcome were consistent across GLT classes and according to the number of GLTs (all interaction P &gt; 0.08). Similarly, we found consistent benefit of dapagliflozin compared with placebo on the secondary end points regardless of background GLT class or number of GLTs. The same applied to the rate of decline in the eGFR rate and safety end points. Dapagliflozin reduced the initiation of insulin therapy during follow-up compared with placebo (hazard ratio 0.72; 95% CI 0.54–0.96; P = 0.025). CONCLUSIONS Dapagliflozin reduced kidney and cardiovascular events in patients with type 2 diabetes and CKD across baseline GLT class or classes in combination." @default.
• W4317548983 created "2023-01-20" @default.
• W4317548983 creator A5001559337 @default.
• W4317548983 creator A5008309890 @default.
• W4317548983 creator A5012551917 @default.
• W4317548983 creator A5012676820 @default.
• W4317548983 creator A5018701033 @default.
• W4317548983 creator A5031624913 @default.
• W4317548983 creator A5038269049 @default.
• W4317548983 creator A5041913215 @default.
• W4317548983 creator A5048450888 @default.
• W4317548983 creator A5060560730 @default.
• W4317548983 creator A5065785268 @default.
• W4317548983 creator A5069865054 @default.
• W4317548983 creator A5071917576 @default.
• W4317548983 date "2023-01-20" @default.
• W4317548983 modified "2023-10-18" @default.
• W4317548983 title "Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study" @default.
• W4317548983 cites W2427094903 @default.
• W4317548983 cites W2597545061 @default.
• W4317548983 cites W2894993577 @default.
• W4317548983 cites W2900413769 @default.
• W4317548983 cites W2905221534 @default.
• W4317548983 cites W2939222610 @default.
• W4317548983 cites W2974260792 @default.
• W4317548983 cites W2993540759 @default.
• W4317548983 cites W3005350465 @default.
• W4317548983 cites W3036492162 @default.
• W4317548983 cites W3081300539 @default.
• W4317548983 cites W3081830235 @default.
• W4317548983 cites W3088173406 @default.
• W4317548983 cites W3092315395 @default.
• W4317548983 cites W3115651139 @default.
• W4317548983 cites W3174397236 @default.
• W4317548983 cites W3193297191 @default.
• W4317548983 cites W3193598686 @default.
• W4317548983 cites W4200310486 @default.
• W4317548983 cites W4200393455 @default.
• W4317548983 cites W4306783667 @default.
• W4317548983 doi "https://doi.org/10.2337/dc22-1514" @default.
• W4317548983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36662635" @default.
• W4317548983 hasPublicationYear "2023" @default.
• W4317548983 type Work @default.
• W4317548983 citedByCount "5" @default.
• W4317548983 countsByYear W43175489832023 @default.
• W4317548983 crossrefType "journal-article" @default.
• W4317548983 hasAuthorship W4317548983A5001559337 @default.
• W4317548983 hasAuthorship W4317548983A5008309890 @default.
• W4317548983 hasAuthorship W4317548983A5012551917 @default.
• W4317548983 hasAuthorship W4317548983A5012676820 @default.
• W4317548983 hasAuthorship W4317548983A5018701033 @default.
• W4317548983 hasAuthorship W4317548983A5031624913 @default.
• W4317548983 hasAuthorship W4317548983A5038269049 @default.
• W4317548983 hasAuthorship W4317548983A5041913215 @default.
• W4317548983 hasAuthorship W4317548983A5048450888 @default.
• W4317548983 hasAuthorship W4317548983A5060560730 @default.
• W4317548983 hasAuthorship W4317548983A5065785268 @default.
• W4317548983 hasAuthorship W4317548983A5069865054 @default.
• W4317548983 hasAuthorship W4317548983A5071917576 @default.
• W4317548983 hasBestOaLocation W43175489831 @default.
• W4317548983 hasConcept C126322002 @default.
• W4317548983 hasConcept C126894567 @default.
• W4317548983 hasConcept C134018914 @default.
• W4317548983 hasConcept C141071460 @default.
• W4317548983 hasConcept C142724271 @default.
• W4317548983 hasConcept C159641895 @default.
• W4317548983 hasConcept C168563851 @default.
• W4317548983 hasConcept C203092338 @default.
• W4317548983 hasConcept C204787440 @default.
• W4317548983 hasConcept C207103383 @default.
• W4317548983 hasConcept C27081682 @default.
• W4317548983 hasConcept C2777180221 @default.
• W4317548983 hasConcept C2777422806 @default.
• W4317548983 hasConcept C2778653478 @default.
• W4317548983 hasConcept C2780306776 @default.
• W4317548983 hasConcept C44249647 @default.
• W4317548983 hasConcept C555293320 @default.
• W4317548983 hasConcept C71924100 @default.
• W4317548983 hasConceptScore W4317548983C126322002 @default.
• W4317548983 hasConceptScore W4317548983C126894567 @default.
• W4317548983 hasConceptScore W4317548983C134018914 @default.
• W4317548983 hasConceptScore W4317548983C141071460 @default.
• W4317548983 hasConceptScore W4317548983C142724271 @default.
• W4317548983 hasConceptScore W4317548983C159641895 @default.
• W4317548983 hasConceptScore W4317548983C168563851 @default.
• W4317548983 hasConceptScore W4317548983C203092338 @default.
• W4317548983 hasConceptScore W4317548983C204787440 @default.
• W4317548983 hasConceptScore W4317548983C207103383 @default.
• W4317548983 hasConceptScore W4317548983C27081682 @default.
• W4317548983 hasConceptScore W4317548983C2777180221 @default.
• W4317548983 hasConceptScore W4317548983C2777422806 @default.
• W4317548983 hasConceptScore W4317548983C2778653478 @default.
• W4317548983 hasConceptScore W4317548983C2780306776 @default.
• W4317548983 hasConceptScore W4317548983C44249647 @default.
• W4317548983 hasConceptScore W4317548983C555293320 @default.
• W4317548983 hasConceptScore W4317548983C71924100 @default.
• W4317548983 hasFunder F4320307770 @default.
• W4317548983 hasIssue "3" @default.

• next